Lucid Diagnostics Inc.
Offers a non-invasive DNA test for early detection of esophageal precancer in at-risk patients.
LUCD | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 360 MADISON AVENUE, 10017 NEW YORK
- Website:
- https://www.luciddx.com/
- Sector:
- Human health and social work activities
- Industry:
- Other residential care activities
Description
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the prevention and early detection of esophageal precancer and cancer. The company's flagship product is the EsoGuard® DNA test, a non-invasive, office-based tool that utilizes targeted Next Generation Sequencing to identify esophageal precancer, including Barrett’s esophagus, in at-risk patients. It is designed for individuals with chronic gastroesophageal reflux disease (GERD) and other risk factors, offering an alternative to traditional endoscopic screening. By enabling early detection, the company aims to improve patient outcomes and reduce mortality from esophageal cancer. Lucid Diagnostics operates as a subsidiary of PAVmed Inc.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Lucid Diagnostics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Lucid Diagnostics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Lucid Diagnostics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
